CD90- (Thy-1-) high selection enhances reprogramming capacity of murine adipose-derived mesenchymal stem cells.
Kawamoto K., Konno M., Nagano H., Nishikawa S., Tomimaru Y., Akita H.
Clinical Trial on Immune Modulation, published in Dis Markers (2013) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Dis Markers (2013)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 24282338
- PMCID
- PMC3824355
- DOI
- 10.1155/2013/392578
- Citations
- 15
Abstract (original English)
Background Mesenchymal stem cells (MSCs), including adipose tissue-derived mesenchymal stem cells (ADSC), are multipotent and can differentiate into various cell types possessing unique immunomodulatory features. Several clinical trials have demonstrated the safety and possible efficacy of MSCs in organ transplantation. Thus, stem cell therapy is promising for tolerance induction. In this study, we assessed the reprogramming capacity of murine ADSCs and found that CD90 (Thy-1), originally discovered as a thymocyte antigen, could be a useful marker for cell therapy. Method Murine ADSCs were isolated from B6 mice, sorted using a FACSAria cell sorter by selection of CD90(Hi) or CD90(Lo), and then transduced with four standard factors (4F; Oct4, Sox2, Klf4, and c-Myc). Results Unsorted, CD90(Hi)-sorted, and CD90(Lo)-sorted murine ADSCs were reprogrammed using standard 4F transduction. CD90(Hi) ADSCs showed increased numbers of alkaline phosphatase-positive colonies compared with CD90(Lo) ADSCs. The relative reprogramming efficiencies of unsorted, CD90(Hi)-sorted, and CD90(Lo)-sorted ADSCs were 100%, 116.5%, and 74.7%, respectively. CD90(Hi) cells were more responsive to reprogramming. Conclusion CD90(Hi) ADSCs had greater reprogramming capacity than CD90(Lo) ADSCs, suggesting that ADSCs have heterogeneous subpopulations. Thus, CD90(Hi) selection presents an effective strategy to is
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Systematic Review with a reported sample of 609 on Hair Loss, Immune Modulation, Autoimmune Research, published in Dermatol Reports (2026) — summary generated from the PubMed abstract.
- 2026
- n = 609
Dermatol Reports - Level ASystematic ReviewPubMed
Regeneration in Aesthetic Medicine: Mechanisms, Evidence, and Clinical Boundaries.
Systematic Review on Skin Aging, Immune Modulation, published in J Cosmet Dermatol (2026) — summary generated from the PubMed abstract.
- 2026
J Cosmet Dermatol - Level ASystematic ReviewEurope PMC
Molecular and Regenerative Effects of Platelet-Rich Plasma and Related Hemocomponents in Animal Models of Liver Injury-A Systematic Review
Systematic Review on Immune Modulation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci - Level ASystematic ReviewPubMed
Stromal Vascular Fraction in Bone Healing: A Systematic Review of Clinical Evidence and Potential Implications in Skull Base Reconstruction and Cranioplasty.
Systematic Review with a reported sample of 214 on Chronic Wound, Immune Modulation, published in J Craniofac Surg (2026) — summary generated from the PubMed abstract.
- 2026
- n = 214
J Craniofac Surg - Level AMeta-analysisEurope PMC
The efficacy and safety of MSCs in GVHD prevention and the treatment of SR-aGVHD: a systematic review and meta-analysis of randomized controlled trials
Meta-analysis on Immune Modulation, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.
- 2026
Stem Cell Res Ther - Level ASystematic ReviewEurope PMC
Harnessing exosomes in dry eye disease: a triple threat approach
Systematic Review on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in BMC Ophthalmol (2026) — summary generated from the PubMed abstract.
- 2026
BMC Ophthalmol